VistaGen Q1 revenue rises on licensing agreement expiration

Vistagen Therapeutics

14/08/2026 13:44

Overview
US biopharma firm's fiscal Q1 revenue rose, driven by licensing agreement expiration
Net loss for fiscal Q1 narrowed from prior year as R&D and G&A expenses declined
Company plans FDA meeting on fasedienol and added neuroscience drug development leaders

Outlook
VistaGen expects R&D expenses to decrease due to cash preservation and completed studies
Company expects G&A expenses to remain at current levels, pending FDA feedback
VistaGen says cash resources expected to fund operations into 2027 but not beyond one year

Result Drivers
LICENSING AGREEMENT - Revenue recognized mainly due to expiration of exclusivity period under Fuji Pharma agreement
COST MANAGEMENT - Lower R&D and G&A expenses due to cash preservation measures and conclusion of key studies

Company press release: ID:nGNX7zCf9B

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Loss Per Share
 
$0.30
 
Q1 Net Loss
 
$13.03 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Vistagen Therapeutics Inc is $1.00, about 275.5% above its August 13 closing price of $0.27

Reuters Recommended Reads
Aug 13 - Dare Bioscience Q2 net loss narrows as revenue rises, R&D expenses decline
Aug 13 - Rani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Aug 13 - Celcuity posts narrower-than-expected loss as R&D costs decreased

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)